ARI-0001 CART19细胞疗法治疗复发/难治性CD19阳性伴孤立性髓外病变急性淋巴细胞白血病患者的结果
该研究评估了18例复发/难治性B细胞急性淋巴细胞白血病伴孤立性髓外病变患者接受CD19 CAR-T细胞ARI-0001治疗的结果,在成人及儿科两个中心进行,包括CART19-BE-01试验及连续同情用药项目。客观缓解率94%(95%CI 73%-99%),完全缓解率78%(95%CI 52%-94%),2年无进展生存率和总生存率分别为49%(95%CI 30%-79%)和61%(95%CI 40%-92%)。结论认为ARI-0001在此类患者中的安全性和有效性特征与骨髓受累患者相当,并与其他CART19产品一致。
要点
- 18例复发/难治性B-ALL伴孤立性髓外病变患者接受ARI-0001治疗,客观缓解率94%,完全缓解率78%。
- 细胞因子释放综合征发生率50%(9/18),无≥3级病例;1例(6%)1级神经毒性;托珠单抗使用率6%(1/18)。
- 2年无进展生存率49%(95%CI 30%-79%),总生存率61%(95%CI 40%-92%),治疗相关死亡率0%。
核心结论
- ARI-0001细胞用于复发/难治性急性淋巴细胞白血病伴孤立性髓外病变患者,其安全性和有效性特征与骨髓受累患者相当,并与其他CART19产品一致。
研究设计与样本
- 研究纳入18例复发/难治性B细胞急性淋巴细胞白血病伴孤立性髓外病变患者,来自成人及儿科两个中心,包括CART19-BE-01试验及连续同情用药项目。
主要发现
- 孤立性髓外病变通过PET-CT检出78%(14/18),和/或通过脑脊液分析检出28%(5/18)。
- 细胞因子释放综合征发生于50%(9/18)患者,无≥3级病例;1例(6%)发生1级神经毒性;托珠单抗用于6%(1/18)患者。
- 2年治疗相关死亡率为0%。
- 客观缓解率94%(95%CI 73%-99%),完全缓解率78%(95%CI 52%-94%)。
- 2年无进展生存率和总生存率分别为49%(95%CI 30%-79%)和61%(95%CI 40%-92%)。
关键数值与推荐
- 患者接受环磷酰胺和氟达拉滨预处理后,输注1×10^6 ARI-0001细胞/kg,初始为单次剂量(首例患者),后分三次输注(10%、30%和60%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated outcomes of 18 patients with isolated extramedullary disease (iEMD) relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with the CD19-directed CAR T cells ARI-0001 in two centers (adult and pediatric), including patients treated in the CART19-BE-01 trial and the consecutive compassionate use program. iEMD was detected by PET-CT in 78% (14/18), and/or by cerebrospinal fluid analysis in 28% (5/18). Patients received cyclophosphamide and fludarabine followed by 1 × 106 ARI-0001 cells/kg, initially as a single dose (first patient) and later split into three fractions (10%, 30%, and 60%). Cytokine release syndrome (CRS) occurred in 50% (9/18) of patients, with no cases of grade ≥3 CRS, and 1 case (6%) of grade 1 neurotoxicity. Tocilizumab was used in 6% of patients (1/18). Procedure-related mortality was 0% at 2 years. Objective responses were seen in 94% (95% confidence interval [CI]: 73%-99%) of patients, with complete responses (CR) seen in 78% (95% CI: 52%-94%) of them. Progression-free and overall survival were 49% (95% CI: 30%-79%) and 61% (95% CI: 40%-92%) at 2 years. In conclusion, the use of ARI-0001 cells in patients with R/R ALL and iEMD was associated with a safety and efficacy profile that is comparable with what is observed in patients with marrow involvement and in line with other CART19 products.
引用
- Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, et al. Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. Am J Hematol. 2022. PMID: 35253928. doi:10.1002/ajh.26519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。